


About Spherix Global Insights

Spherix is the world's leading Life Sciences market intelligence and advisory services firm, providing unrivaled knowledge and the most informed, actionable insights.

We bring human intelligence to market intelligence. Spherix empowers customers to access critical insights that drive successful decision-making through deep, expert knowledge.



Spherix Provides Independent Expertise in Seven Areas


Dermatology

Nephrology

Gastroenterology

Neurology

Rheumatology

Ophthalmology

Hematology/Oncology

This is a guide to the publications Spherix will produce in 2024. It is organized by therapeutic area, indication, and deliverable.

Going Beyond the Data

The report is only the beginning. Spherix brings curation and interpretation to market intelligence, working closely with customers to reveal actionable insights that transform markets.

Type of Publications

MARKET DYNAMIX	A yearly market overview of an indication, <i>Market Dynamix</i> provides insights into current treatment paradigms and unmet patient needs as well as physician opinions on how they will likely prescribe new products upon approval.
REALTIME DYNAMIX	A US quarterly or EU5 semi-annual update on an indication, <i>RealTime Dynamix</i> provides trending content on brand use, future intentions, promotional activity, disease awareness and controversy, and pipeline product perceptions.
LAUNCH DYNAMIX	Published monthly, <i>Launch Dynamix</i> tracks a new brand's first eighteen months of commercial availability. Each quarter includes a deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.
PATIENT CHART DYNAMIX	A yearly large-scale patient chart audit on an indication, <i>Patient Chart Dynamix</i> unmasks real patient management patterns and uncovers the "why" behind treatment decisions.
PATIENT VOICE DYNAMIX	An independent service that explores the voice of the patient as they progress through their disease and treatment journeys.
PAYER DYNAMIX	Empowers pharmaceutical companies with forward-looking insights from key payer decision makers – enabling market access, brand, and strategy teams to confidently navigate evolving coverage and reimbursement landscapes, while preparing for potential policy-driven disruptions.
SPECIAL TOPIX	Whether the focus is breaking industry news, ongoing trends, conference coverage, or quick-pulse reactions, <i>Special Topix</i> assesses the impact of events in our specialty markets.

For a complete index of available reports, visit
www.clientportal.spherixglobalinsights.com



2026 Dermatology Publications

SPHERIX
GLOBAL INSIGHTS

Alopecia Areata	
MARKET DYNAMIX	<ul style="list-style-type: none"> Alopecia Areata, US
LAUNCH DYNAMIX	<ul style="list-style-type: none"> Leqselvi (SUN Pharma) in Alopecia Areata, US
Atopic Dermatitis	
MARKET DYNAMIX	<ul style="list-style-type: none"> Atopic Dermatitis, US Atopic Dermatitis, JP
REALTIME DYNAMIX	<ul style="list-style-type: none"> Atopic Dermatitis, EU5
LAUNCH DYNAMIX	<ul style="list-style-type: none"> Ebglyss (Eli Lilly) in Atopic Dermatitis, US Nemluvio (Galderma) in Atopic Dermatitis, US Vtama and Zoryve (Organon/ Arcutis) in Atopic Dermatitis, US
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"> Atopic Dermatitis, US
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"> Atopic Dermatitis, US
Chronic Spontaneous Urticaria	
MARKET DYNAMIX	<ul style="list-style-type: none"> Chronic Spontaneous Urticaria, US
LAUNCH DYNAMIX	<ul style="list-style-type: none"> Dupixent (Sanofi/Regeneron) in CSU, US Rhapsido (Novartis) in CSU, US
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"> Chronic Spontaneous Urticaria, US
Cross Indications / Specialty	
SPECIAL TOPIX	<ul style="list-style-type: none"> Biologic Coordinators Across Dermatology, US Payer Management Strategies, US

Hidradenitis Suppurativa	
MARKET DYNAMIX	<ul style="list-style-type: none"> Hidradenitis Suppurativa, US Hidradenitis Suppurativa, EU5
LAUNCH DYNAMIX	<ul style="list-style-type: none"> Bimzelx (UCB) in Hidradenitis Suppurativa, US
Plaque Psoriasis	
REALTIME DYNAMIX	<ul style="list-style-type: none"> Plaque Psoriasis, US Plaque Psoriasis, EU5
LAUNCH DYNAMIX	<ul style="list-style-type: none"> Icotrokinra (J&J) in Plaque Psoriasis, US
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"> Plaque Psoriasis, US
SPECIAL TOPIX	<ul style="list-style-type: none"> The Oral Opportunity in Plaque Psoriasis, US
Prurigo Nodularis	
MARKET DYNAMIX	<ul style="list-style-type: none"> Prurigo Nodularis, US
LAUNCH DYNAMIX	<ul style="list-style-type: none"> Nemluvio (Galderma) in Prurigo Nodularis, US
Other Dermatology Indications	
MARKET DYNAMIX	<ul style="list-style-type: none"> Asthma, US Asthma, EU Chronic Obstructive Pulmonary Disease, US Chronic Obstructive Pulmonary Disease, EU Vitiligo, US



MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPIX	Current events on specific interest areas



Eosinophilic Esophagitis

MARKET DYNAMIX

- *Eosinophilic Esophagitis, US*

Inflammatory Bowel Disease

MARKET DYNAMIX

- *Crohn's Disease, JP*
- *Ulcerative Colitis, JP*

REALTIME DYNAMIX

- *Crohn's Disease, US*
- *Crohn's Disease, EU5*
- *Ulcerative Colitis, US*
- *Ulcerative Colitis, EU5*

LAUNCH DYNAMIX

- *Tremfya (Janssen) in Crohn's Disease, US*
- *Omvooh (Eli Lilly) in Crohn's Disease, US*
- *Tremfya (Janssen) in Ulcerative Colitis, US*

PATIENT CHART DYNAMIX

- *Inflammatory Bowel Disease New Starts, US*
- *Inflammatory Bowel Disease Switching, US*
- *Inflammatory Bowel Disease Switching, EU5*

PATIENT VOICE DYNAMIX

- *Inflammatory Bowel Disease, US*

SPECIAL TOPIX

- *Biologic Coordinators in Gastroenterology, US*
- *The Role of APPs in IBD*

Obesity

MARKET DYNAMIX

- *Obesity, US*

LAUNCH DYNAMIX

- *Oral Semaglutide (Novo Nordisk) in Obesity, US*
- *Orforglipron (Eli Lilly) in Obesity, US*
- *CagriSema (Novo Nordisk) in Obesity, US*

MASH

MARKET DYNAMIX

- *MASH, US*
- *MASH, EU5*

LAUNCH DYNAMIX

- *Rezdiffra (Madrigal) in MASH, US*
- *Wegovy (Novo Nordisk) in MASH, US*

PATIENT CHART DYNAMIX

- *MASH, US*

SPECIAL TOPIX

- *MASH Screening and Management among PCPs and Endocrinologists, US*

Other Gastroenterology Indications

MARKET DYNAMIX

- *Celiac Disease, US*

REALTIME DYNAMIX

- *Irritable Bowel Syndrome, US*

LAUNCH DYNAMIX

- *Iqirvo (Ipsen) in Primary Biliary Cholangitis, US*
- *Linerixibat (GSK) in Cholestatic Pruritus Among PBC Patients, US*
- *Livdelzi (Gilead/ Cymabay) in Primary Biliary Cholangitis, US*

SPECIAL TOPIX

- *The Business of Gastroenterology, US*

Cross Specialty

SPECIAL TOPIX

- *Payer Management Strategies, US*

Key

MARKET DYNAMIX

Yearly market overview of key indication

REALTIME DYNAMIX

Quarterly (US) or semi-annual (EU5) indication updates

LAUNCH DYNAMIX

Monthly benchmark of newly launched products

PATIENT CHART DYNAMIX

Yearly review of large-scale patient chart audits

PATIENT VOICE DYNAMIX

Independent service capturing patient journey insights

PAYER DYNAMIX

Payer priorities and tactics compared across therapy areas

SPECIAL TOPIX

Current events on specific interest areas



2026 Rheumatology Publications

Lupus	
MARKET DYNAMIX	<ul style="list-style-type: none"> Cutaneous Lupus, US (2026 refresh) Systemic Lupus Erythematosus, US Systemic Lupus Erythematosus Pipeline Refresh, US Systemic Lupus Erythematosus, EU5 Lupus Nephritis, China
REALTIME DYNAMIX	<ul style="list-style-type: none"> Lupus Nephritis, US Lupus Nephritis, EU5 Lupus Nephritis, Brazil Lupus Nephritis, Canada
LAUNCH DYNAMIX	<ul style="list-style-type: none"> Gazyva (Genentech) in Lupus Nephritis, US
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"> Lupus Nephritis, US Systemic Lupus Erythematosus, US Systemic Lupus Erythematosus & Lupus Nephritis, EU5 Cutaneous Lupus, US
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"> Systemic Lupus Erythematosus & Lupus Nephritis, US

Other Rheumatology Indications	
MARKET DYNAMIX	<ul style="list-style-type: none"> Idiopathic Inflammatory Myopathies, US (2026 Refresh) Rheumatoid Arthritis, US (2026 Refresh) Rheumatoid Arthritis, EU5 (2025) Sjogren's Disease, US (2025) Systemic Sclerosis, US
LAUNCH DYNAMIX	<ul style="list-style-type: none"> Rinvoq (AbbVie) in Giant Cell Arteritis, US Ianalumab (Novartis) in Sjogren's Disease, US*
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"> Systemic Sclerosis, US
SPECIAL TOPIX	<ul style="list-style-type: none"> ILD in Rheumatology, US (2026 Refresh) Cell Therapy in Rheumatology, US Biologic Coordinators Across Rheumatology, US
Cross Specialty	
SPECIAL TOPIX	<ul style="list-style-type: none"> Payer Management Strategies, US

Spondyloarthritis (AS, nr-AxSpA, and PsA)

MARKET DYNAMIX	<ul style="list-style-type: none"> Ankylosing Spondylitis & nr-AxSpA, US Ankylosing Spondylitis & nr-AxSpA, EU5 (2025) Psoriatic Arthritis, EU5 (2025)
REALTIME DYNAMIX	<ul style="list-style-type: none"> Psoriatic Arthritis, US
LAUNCH DYNAMIX	<ul style="list-style-type: none"> Bimzelx (UCB) in AS & nr-AxSpA, US Bimzelx (UCB) in Psoriatic Arthritis, US Sotykto (BMS) in Psoriatic Arthritis, US*

Key	MARKET DYNAMIX Yearly market overview of key indication REALTIME DYNAMIX Quarterly (US) or semi-annual (EU5) indication updates LAUNCH DYNAMIX Monthly benchmark of newly launched products PATIENT CHART DYNAMIX Yearly review of large-scale patient chart audits PATIENT VOICE DYNAMIX Independent service capturing patient journey insights PAYER DYNAMIX Payer priorities and tactics compared across therapy areas SPECIAL TOPIX Current events on specific interest areas
-----	--



Rare Disease	
MARKET DYNAMIX	<ul style="list-style-type: none"> Membranous Nephropathy, US
REALTIME DYNAMIX	<ul style="list-style-type: none"> IgA Nephropathy, US IgA Nephropathy, EU5
LAUNCH DYNAMIX	<ul style="list-style-type: none"> Fabhalta in C3G Empaveli in C3G Fabhalta in IgAN Vanrafia in IgAN Sibreprenlimab in IgAN Filspari in FSGS* Atacicept in IgAN* Povetacicept in IgAN*
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"> Focal Segmental Glomerulosclerosis, US IgA Nephropathy, US IgA Nephropathy, EU5 IgA Nephropathy, JP IgA Nephropathy, China
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"> IgA Nephropathy, US

CKD, Dialysis & Transplant	
MARKET DYNAMIX	<ul style="list-style-type: none"> Transplant Rejection, US
REALTIME DYNAMIX	<ul style="list-style-type: none"> Dialysis–Nephrologists, US Dialysis, Renal Dietitians/NP/PA, US
LAUNCH DYNAMIX	<ul style="list-style-type: none"> Vafseo (Akebia) in Renal Anemia, US OLC (Unicycive) in Hyperphosphatemia, US*
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"> Chronic Kidney Disease, Non-Dialysis, Nephrologists, US Chronic Kidney Disease, Non-Dialysis, PCPs, US Dialysis, US
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"> Chronic Kidney Disease, US
SPECIAL TOPIX	<ul style="list-style-type: none"> Feedback from ASN Kidney Week, US
Cross Specialty	
SPECIAL TOPIX	<ul style="list-style-type: none"> Payer Management Strategies, US

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPIX	Current events on specific interest areas



Alzheimer's Disease

MARKET DYNAMIX

- Alzheimer's Disease, US

PATIENT VOICE DYNAMIX

- Alzheimer's Disease, US

Migraine

REALTIME DYNAMIX

- Migraine, 2 Wave, US

Multiple Sclerosis

MARKET DYNAMIX

- Multiple Sclerosis, US

LAUNCH DYNAMIX

- Tolebrutinib, (Sanofi) nrSPMS, US

Psychiatric Indications

MARKET DYNAMIX

- Psychosis in Schizophrenia, US
- Major Depressive Disorder (MDD), US
- Schizophrenia, US

Generalized Myasthenia Gravis

REALTIME DYNAMIX

- Generalized Myasthenia Gravis, US
- Generalized Myasthenia Gravis, EU5

PATIENT CHART DYNAMIX

- Generalized Myasthenia Gravis, US
- Generalized Myasthenia Gravis, EU5

PATIENT VOICE DYNAMIX

- Generalized Myasthenia Gravis, US

LAUNCH DYNAMIX

- Uplizna, (Amgen) Generalized Myasthenia Gravis (gMG), US
- Imaavy, (J&J) Generalized Myasthenia Gravis (gMG), US
- Gefurulimab, (Alexion/AZ) Generalized Myasthenia Gravis (gMG), US*
- Cemdisiran, (Regeneron) Generalized Myasthenia Gravis (gMG), US*

Other Neurology Indications

MARKET DYNAMIX

- Chronic Inflammatory Demyelinating Polyneuropathy, US

SPECIAL TOPIX

- Cell Therapy in Neurology Indications, US

Cross Specialty

SPECIAL TOPIX

- Payer Management Strategies, US

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPIX	Current events on specific interest areas



Diabetic Macular Edema & Neovascular Age-Related Macular Degeneration

REALTIME
DYNAMIX

- *Diabetic Macular Edema & AMD, US*

Cross Specialty

SPECIAL
TOPIX

- *Payer Management Strategies, US*

Neovascular Age-Related Macular Degeneration

PATIENT CHART
DYNAMIX

- *Age-Related Macular Degeneration, US*

Other Ophthalmology Indications

MARKET
DYNAMIX

- *Diabetic Retinopathy, US*

SPECIAL
TOPIX

- *Gene Therapies in Retina, US*

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPIX	Current events on specific interest areas



2026 Hematology/Oncology Publications

SPHERIX
GLOBAL INSIGHTS

B-Cell Malignancies		Cross Specialty		Paroxysmal Nocturnal Hemoglobinuria	
MARKET DYNAMIX	<ul style="list-style-type: none"> B-Cell Malignancies, US Large B-Cell Lymphoma, EU 	SPECIAL TOPIX	<ul style="list-style-type: none"> Payer Management Strategies, US 	MARKET DYNAMIX	<ul style="list-style-type: none"> Paroxysmal Nocturnal Hemoglobinuria, US
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"> Large B-Cell Lymphoma, EU Chronic Lymphocytic Leukemia, US 	REALTIME DYNAMIX	<ul style="list-style-type: none"> PD-1 Inhibition in Solid Tumors, US 	PATIENT CHART DYNAMIX	<ul style="list-style-type: none"> Paroxysmal Nocturnal Hemoglobinuria, US
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"> B-Cell Malignancies, US 	Solid Tumors		Other Benign Hematology Indications	
Bleeding Disorders		Multiple Myeloma		MARKET DYNAMIX	<ul style="list-style-type: none"> Warm Autoimmune Hemolytic Anemia (w-AIHA) Immune Thrombocytopenic Purpura (ITP)
MARKET DYNAMIX	<ul style="list-style-type: none"> Hemophilia A & B, US Hemophilia A & B, EU5 Von Willebrand Disease, US 	MARKET DYNAMIX	<ul style="list-style-type: none"> Multiple Myeloma, EU5 	LAUNCH DYNAMIX	<ul style="list-style-type: none"> Nipocalimab in w-AIHA* Wayrilz in ITP
LAUNCH DYNAMIX	<ul style="list-style-type: none"> Qfitlia in Hemophilia A & B Hympavzi in Hemophilia A & B Alhemo in Hemophilia A & B 	REALTIME DYNAMIX	<ul style="list-style-type: none"> Multiple Myeloma, US 		
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"> People with Bleeding Disorders 	PATIENT CHART DYNAMIX	<ul style="list-style-type: none"> Multiple Myeloma, US 		
SPECIAL TOPIX	<ul style="list-style-type: none"> Women, Girls, and people who have or have had the potential to menstruate (WGPPM) with Bleeding Disorders 	SPECIAL TOPIX	<ul style="list-style-type: none"> Smoldering Myeloma, US 		
Hemoglobinopathies		Acute Myeloid Leukemia			
MARKET DYNAMIX	<ul style="list-style-type: none"> Sickle Cell Disease, US Thalassemia, US 	REALTIME DYNAMIX	<ul style="list-style-type: none"> Acute Myeloid Leukemia, US 		
LAUNCH DYNAMIX	<ul style="list-style-type: none"> Mitapivat in Thalassemia* 	PATIENT CHART DYNAMIX	<ul style="list-style-type: none"> Acute Myeloid Leukemia, US 		
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"> Sickle Cell Disease, US Thalassemia, US 	Myeloproliferative Neoplasms (MPN)			
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"> Sickle Cell Disease, US 	MARKET DYNAMIX	<ul style="list-style-type: none"> Myeloproliferative Neoplasms, US 		
		<p>MARKET DYNAMIX Yearly market overview of key indication REALTIME DYNAMIX Quarterly (US) or semi-annual (EU5) indication updates LAUNCH DYNAMIX Monthly benchmark of newly launched products PATIENT CHART DYNAMIX Yearly review of large-scale patient chart audits PATIENT VOICE DYNAMIX Independent service capturing patient journey insights PAYER DYNAMIX Payer priorities and tactics compared across therapy areas SPECIAL TOPIX Current events on specific interest areas</p>			

Visit The Spherix Portal



Looking for more? Visit the Spherix Portal

The Spherix Portal helps clients interact with their data and insights so they can find answers to their important questions.

By using the portal, Spherix clients can access all their subscribed data and easily integrate intelligence into their research projects.

Access to the Spherix Portal is open to anyone. It's the best way to find the right product to fit your needs.

Create your free account at
www.clientportal.spherixglobalinsights.com